Pharma

  • An Eli Lilly logo is seen at the top of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Pain drugs

    Lilly quietly cuts a pain drug from its pipeline

    The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company’s "high internal bar for success," a spokesperson said.

    By • Oct. 31, 2025
  • Close up of Wall Street sign, with tall buildings in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Earnings roundup: Alnylam’s down day, Neurocrine’s head scratch and Biogen’s ‘low quality’ win

    Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called “lackluster” appeal and Bristol Myers’ prized schizophrenia drug again underwhelmed.

    By , • Oct. 30, 2025
  • An illustration of beta amyloid plaques and tau in the brain Explore the Trendline➔
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Alzheimer's disease

    Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

    By BioPharma Dive staff
  • Weight loss GLP-1
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly hikes revenue forecasts on booming obesity drug sales

    Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, officially becoming the world’s best-selling drug. 

    By Kristin Jensen • Oct. 30, 2025
  • Close-up view of the Novo Nordisk logo mounted on the exterior wall of a building. The logo features a stylized blue Apis bull with a sun disk above its head, symbolizing the company's identity. The background shows a tan brick wall and part of a leafless tree in the foreground under a clear blue sky."
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Obesity drugs

    Novo tops Pfizer with $6.5B bid for Metsera

    The offer sparked a bidding war between the two large pharmas over the obesity drug specialist, with Pfizer alleging Novo’s offer is “illusory” and “structured in a way to circumvent antitrust laws.”

    By • Updated Oct. 30, 2025
  • Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma characterized by cytoplasmic clearing and a pattern of small branching blood vessels.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck kidney cancer drug succeeds in two large trials

    The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its top-selling immunotherapy Keytruda loses patent protection. 

    By • Oct. 28, 2025
  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis’ $12B Avidity deal shows a willingness to take big swings in neuroscience

    A 46% premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at technology that fits into its own expertise.

    By Michael Gibney • Oct. 28, 2025
  • The Bayer logo hangs on the side of a building.
    Image attribution tooltip
    Maja Hitij via Getty Images
    Image attribution tooltip

    Bayer receives FDA approval for non-hormonal menopause therapy

    Clearance of Lynkuet provides a new alternative to hormone-based treatment for hot flashes and sets up a market battle with Astellas Pharma’s Veozah.

    By • Oct. 27, 2025
  • Pharmacist at work.
    Image attribution tooltip
    Permission granted by Walgreens
    Image attribution tooltip
    Sponsored by Walgreens

    Community pharmacies and BioPharma: Advancing whole-patient care together

    As healthcare grows more complex, community pharmacies can help simplify and coordinate patient care. 

    Oct. 27, 2025
  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease

    The deal, which Novartis expects can “unlock multibillion-dollar opportunities” in the years ahead, hands the company a group of medicines for multiple forms of muscular dystrophy.

    By • Oct. 26, 2025
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip
    Vaccines

    Sanofi says ‘soft’ start to fall immunizations slowed vaccine sales

    The French pharma’s overall vaccine sales declined 8% in the quarter, with a key driver being slower-than-usual uptake of flu shots in the U.S.

    By • Oct. 24, 2025
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA clears return of GSK’s once-withdrawn multiple myeloma drug

    The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market only two years later.

    By • Oct. 23, 2025
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi drug acquired in buyout succeeds in rare disease trial

    The drug’s success in a Phase 2 study in alpha-1 antitrypsin deficiency “validates” Sanofi’s 2024 acquisition of Inhibrx, according to one analyst.

    By • Oct. 22, 2025
  • Calley Means speaks at HLTH 2025
    Image attribution tooltip
    Courtesy of HLTH 2025
    Image attribution tooltip

    Top RFK aide lashes out against healthcare industry for profiting off of illness

    Calley Means stopped short of accusing hospitals, insurers and drug companies from actively working to keep Americans sick, but said it was an "economic fact" that the companies benefit financially when people are ill.

    By Susanna Vogel • Oct. 22, 2025
  • A sign with the logo for the Takeda pharmaceutical company.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Takeda stakes more than $11B on cancer drugs from China

    The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be “transformative” for its oncology portfolio.

    By • Oct. 22, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Iambic partners with Jazz; Merck breaks ground on $3B plant

    The biotechs will assess a combination of two drugs against HER2-positive breast cancer. Elsewhere, Merck unveiled the latest piece of its more than $70 billion domestic manufacturing investment.

    By BioPharma Dive staff • Oct. 21, 2025
  • Close-up view of the Novo Nordisk logo mounted on the exterior wall of a building. The logo features a stylized blue Apis bull with a sun disk above its head, symbolizing the company's identity. The background shows a tan brick wall and part of a leafless tree in the foreground under a clear blue sky."
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Novo’s main shareholder pushes out more than half of company’s board

    The Novo Foundation chair said the current board of the Wegovy maker, which is already dealing with layoffs and a CEO change, was too slow to react to obesity market shifts.

    By • Oct. 21, 2025
  • Colleagues working in a lab or data center
    Image attribution tooltip

    AdobeStock/1107050561

    Image attribution tooltip
    Sponsored by Panalgo

    From weeks to minutes: How generative AI transforms pharma data and ROI

    GenAI is changing how pharma teams work — making data accessible, transparent, and actionable.

    By Niyati Parikh, VP, Product Readiness, Panalgo • Oct. 20, 2025
  • Scientific illustration of a migrating breast cancer cell
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roche pill delays tumor progression in closely watched breast cancer study

    Results presented at the European Society for Medical Oncology meeting could help separate Roche’s medicine from similar hormone-degrading drugs for breast tumors.

    By • Oct. 18, 2025
  • A micrograph of a myeloma neoplasm in a bone marrow biopsy.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    J&J claims success in study testing earlier Tecvayli use in multiple myeloma

    The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to later-line settings for the persistent blood cancer.

    By • Oct. 16, 2025
  • View of the Novartis logo on the Banting 1 building, Novartis Campus Basel.
    Image attribution tooltip
    Courtesy of Novartis
    Image attribution tooltip

    Novartis confirms drug’s benefits in rare kidney disease as competitors loom

    The findings position Fabhalta to secure a standard approval in IgA nephropathy — a crowded area of drug research — at a time when newer types of medicines are quickly advancing.

    By Kristin Jensen • Oct. 16, 2025
  • White flags bearing Novo Nordisk's logo are seen against a blue sky.
    Image attribution tooltip
    Courtesy of Novo Nordisk
    Image attribution tooltip

    Novo wagers up to $2.1B on Omeros’ rare disease drug

    The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called complement-mediated diseases.

    By • Oct. 15, 2025
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly, battling skepticism, reinforces GLP-1 pill’s case with new study data

    Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where on Wednesday it succeeded in two more late-stage trials. 

    By Kristin Jensen • Oct. 15, 2025
  • This image depicts the podcast series cover image for Pearson's BioPharma Dive series, "The Progress Profile: Alzheimer’s Research in Focus"
    Image attribution tooltip
    William Walker/BioPharma Dive
    Image attribution tooltip
    Sponsored by Pearson

    [Podcast] The Progress Profile: Alzheimer’s Research in Focus

    Discover the latest breakthroughs in Alzheimer's research, diagnosis, and prevention in this expert-led podcast series.

    By BioPharma Dive's studioID • Oct. 15, 2025
  • A wall bearing the Johnson & Johnson logo is seen outside of an office building.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip

    J&J plans to spin out orthopedics business

    CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such as cardiovascular and robotics.

    By Ricky Zipp • Oct. 14, 2025
  • An illustration of B cells producing antibodies
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Bristol’s $1.5B Orbital buyout extends ‘in vivo’ cell therapy deal streak

    The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically modify immune cells inside the body. 

    By • Oct. 10, 2025